Over the past three decades, the interpretation of clinical trial outcomes in studies of advanced-stage non-small-cell lung cancer has changed. The robustness of findings from these trials has been called into question. We believe this [more]
Large randomised phase III trials conducted in patients with non-small-cell lung cancer (NSCLC) harbouring activating mutations in EGFR have demonstrated that erlotinib or gefitinib are superior to platinum-based chemotherapy. Download full article
Selected reports edited by Janet Fricker Download full article
Selected reports edited by Janet Fricker Download full article